- Home
- GECC vs MCRB Comparison
GECC vs MCRB Comparison
Compare GECC & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- MCRB
- Stock Information
- Founded
- GECC 2016
- MCRB 2010
- Country
- GECC United States
- MCRB United States
- Employees
- GECC N/A
- MCRB N/A
- Industry
- GECC Finance: Consumer Services
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- GECC Finance
- MCRB Health Care
- Exchange
- GECC Nasdaq
- MCRB Nasdaq
- Market Cap
- GECC 127.9M
- MCRB 144.6M
- IPO Year
- GECC N/A
- MCRB 2015
- Fundamental
- Price
- GECC $7.86
- MCRB $16.10
- Analyst Decision
- GECC Strong Buy
- MCRB Hold
- Analyst Count
- GECC 1
- MCRB 3
- Target Price
- GECC $11.50
- MCRB $14.33
- AVG Volume (30 Days)
- GECC 254.0K
- MCRB 92.0K
- Earning Date
- GECC 11-04-2025
- MCRB 11-05-2025
- Dividend Yield
- GECC 19.47%
- MCRB N/A
- EPS Growth
- GECC 29.91
- MCRB N/A
- EPS
- GECC 1.58
- MCRB 10.22
- Revenue
- GECC $47,638,000.00
- MCRB N/A
- Revenue This Year
- GECC $30.29
- MCRB N/A
- Revenue Next Year
- GECC N/A
- MCRB N/A
- P/E Ratio
- GECC $4.96
- MCRB $1.64
- Revenue Growth
- GECC 29.12
- MCRB N/A
- 52 Week Low
- GECC $7.18
- MCRB $6.53
- 52 Week High
- GECC $11.46
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- GECC 38.75
- MCRB 34.35
- Support Level
- GECC $7.50
- MCRB $15.51
- Resistance Level
- GECC $7.99
- MCRB $18.38
- Average True Range (ATR)
- GECC 0.23
- MCRB 1.16
- MACD
- GECC 0.16
- MCRB -0.39
- Stochastic Oscillator
- GECC 83.95
- MCRB 11.05
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.